EDARAVONE DIN 02569604
Status: Approved
Holder: SHIONOGI CANADA INC.
Available to quote
Health Canada record
| Active ingredient(s) | EDARAVONE 105 MG |
|---|
| Dosage form | Suspension |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | N07XX14 EDARAVONE |
|---|
| Original market date | |
|---|
| Current status date | 26-Jun-2026 |
|---|
| Source | Health Canada DPD |
|---|
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing EDARAVONE
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02532611 | RADICAVA | SHIONOGI INC. | Suspension | EDARAVONE 105 MG | Marketed |
| 02475472 | RADICAVA | MITSUBISHI TANABE PHARMA CORPORATION | Solution | EDARAVONE 30 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 37783 | 2026-06-26 | New Drug Submission (NDS) | Administrative: Licensing Agreement between two manufacturers |
International API supply for EDARAVONE
13 active FDA Drug Master Files.
Request a quote for EDARAVONE
How to read a Canadian DIN record